Cancer patients are known to be vulnerable to infection in general and may experience more serious consequences of COVID-1914–17, but little is known of whether ACE2 and TMPRSS2 are expressed in colorectal cancer tissues, or how infection with SARS-CoV-2 may affect the clinical course of patients with colorectal cancer. This evidence concerns the gene ACE2 and infection.